3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
18
Active not recruiting
16
Recruiting
8
Terminated
3
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Breast Cancer Female
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
durvalumab
×
Clear all
NCT03872505
2021-08-25
PANDoRA
Cedars-Sinai Medical Center
Phase 2
Withdrawn